EP3525798A4 - METHOD FOR REDUCING PROTEINURIA IN A HUMAN TEST Suffering From Immunoglobulin-A Nephropathy - Google Patents

METHOD FOR REDUCING PROTEINURIA IN A HUMAN TEST Suffering From Immunoglobulin-A Nephropathy Download PDF

Info

Publication number: EP3525798A4
Authority: EP; European Patent Office
Prior art keywords: nephropathy; immunoglobulin; human test; reducing proteinuria; suffering
Prior art date: 2016-10-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP17861108.3A

Other languages

German (de)

French (fr)

Other versions

EP3525798A1 (en

Inventor

Nigel John BRUNSKILL

Gregory A. Demopulos

Tom DUDLER

Hans-Wilhelm Schwaeble

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Leicester

Omeros Corp

Original Assignee

University of Leicester

Omeros Medical Systems Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-13

Filing date

2017-10-12

Publication date

2020-07-08

2017-01-05 Priority claimed from US15/399,524 external-priority patent/US10736960B2/en

2017-03-27 Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en

2017-10-12 Application filed by University of Leicester, Omeros Medical Systems Inc filed Critical University of Leicester

2019-08-21 Publication of EP3525798A1 publication Critical patent/EP3525798A1/en

2020-07-08 Publication of EP3525798A4 publication Critical patent/EP3525798A4/en

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Environmental Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Biodiversity & Conservation Biology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Animal Husbandry (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

EP17861108.3A 2016-10-13 2017-10-12 METHOD FOR REDUCING PROTEINURIA IN A HUMAN TEST Suffering From Immunoglobulin-A Nephropathy Pending EP3525798A4 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201662407979P	2016-10-13	2016-10-13
US15/399,524 US10736960B2 (en)	2016-01-05	2017-01-05	Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en)	2016-01-05	2017-03-27	Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P	2017-06-30	2017-06-30
PCT/US2017/056386 WO2018071701A1 (en)	2016-10-13	2017-10-12	Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Publications (2)

Publication Number	Publication Date
EP3525798A1 EP3525798A1 (en)	2019-08-21
EP3525798A4 true EP3525798A4 (en)	2020-07-08

Family

ID=61906454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17861108.3A Pending EP3525798A4 (en)	2016-10-13	2017-10-12	METHOD FOR REDUCING PROTEINURIA IN A HUMAN TEST Suffering From Immunoglobulin-A Nephropathy

Country Status (19)

Country	Link
EP (1)	EP3525798A4 (en)
JP (1)	JP6893554B2 (en)
KR (1)	KR102348939B1 (en)
CN (2)	CN116726163A (en)
AU (1)	AU2017342428B2 (en)
BR (1)	BR112019007426A2 (en)
CA (2)	CA3210384A1 (en)
CL (2)	CL2019000909A1 (en)
GE (1)	GEP20247587B (en)
IL (1)	IL265981B2 (en)
JO (1)	JOP20190068A1 (en)
MA (1)	MA46541A (en)
MX (1)	MX2019004074A (en)
MY (1)	MY205849A (en)
PH (1)	PH12019500711B1 (en)
SG (1)	SG11201902941UA (en)
UA (1)	UA126908C2 (en)
WO (1)	WO2018071701A1 (en)
ZA (1)	ZA201902933B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111419860A (en) *	2020-03-19	2020-07-17	长春市儿童医院	Glomerular lobular nephropathy modeling method
CN115215937B (en) *	2021-04-15	2023-05-26	上海麦济生物技术有限公司	Anti-human MASP-2 antibody, preparation method and application thereof
EP4444758A2 (en)	2021-12-10	2024-10-16	Omeros Corporation	Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
CN116392488B (en) *	2023-05-22	2025-03-28	中南大学湘雅医院	Application of an alkaloid compound in the preparation of a drug for preventing and treating diabetic nephropathy
CN117016486B (en) *	2023-07-20	2024-05-14	上海澎立生技医药研究有限公司	Animal model construction method for IgA nephropathy combined membranous nephropathy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012151481A1 (en) *	2011-05-04	2012-11-08	Omeros Corporation	Compositions for inhibiting masp-2 dependent complement acitivation
US20130266560A1 (en) *	2011-04-08	2013-10-10	University Of Leicester	Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
WO2015058143A1 (en) *	2013-10-17	2015-04-23	Omeros Corporation	Methods for treating conditions associated with masp-2 dependent complement activation
US20180153988A1 (en) *	2016-08-31	2018-06-07	Omeros Corporation	Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2374819T (en) *	2003-05-12	2017-07-04	Helion Biotech Aps	Antibodies to masp-2
US8840893B2 (en) *	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) *	2004-06-10	2014-02-27	University Of Leicester	Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) *	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) *	2006-03-31	2009-12-01	Eastman Kodak Company	Method of making a multilevel halftone screen
CN106390117A (en) *	2009-10-16	2017-02-15	奥默罗斯公司	Methods for treating conditions associated with masp-2 dependent complement activation
US9102721B2 (en) *	2011-01-21	2015-08-11	Fibrogen, Inc.	Therapeutic method
KR20220044616A (en) *	2011-04-08	2022-04-08	유니버시티 오브 레스터	Methods for treating conditions associated with masp-2 dependent complement activation
US20150017162A1 (en) *	2013-03-15	2015-01-15	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CN117503923A (en) *	2016-01-05	2024-02-06	莱斯特大学	Methods for inhibiting fibrosis in a subject in need thereof

2017
- 2017-06-16 JO JOP/2019/0068A patent/JOP20190068A1/en unknown
- 2017-10-12 UA UAA201904866A patent/UA126908C2/en unknown
- 2017-10-12 CN CN202310450575.2A patent/CN116726163A/en active Pending
- 2017-10-12 IL IL265981A patent/IL265981B2/en unknown
- 2017-10-12 MY MYPI2019001798A patent/MY205849A/en unknown
- 2017-10-12 KR KR1020197012865A patent/KR102348939B1/en active Active
- 2017-10-12 CA CA3210384A patent/CA3210384A1/en active Pending
- 2017-10-12 AU AU2017342428A patent/AU2017342428B2/en active Active
- 2017-10-12 WO PCT/US2017/056386 patent/WO2018071701A1/en not_active Ceased
- 2017-10-12 EP EP17861108.3A patent/EP3525798A4/en active Pending
- 2017-10-12 GE GEAP201715070A patent/GEP20247587B/en unknown
- 2017-10-12 MX MX2019004074A patent/MX2019004074A/en unknown
- 2017-10-12 SG SG11201902941UA patent/SG11201902941UA/en unknown
- 2017-10-12 JP JP2019520140A patent/JP6893554B2/en active Active
- 2017-10-12 PH PH1/2019/500711A patent/PH12019500711B1/en unknown
- 2017-10-12 CN CN201780060710.5A patent/CN110177557A/en active Pending
- 2017-10-12 BR BR112019007426A patent/BR112019007426A2/en active Search and Examination
- 2017-10-12 MA MA046541A patent/MA46541A/en unknown
- 2017-10-12 CA CA3039927A patent/CA3039927C/en active Active
2019
- 2019-04-04 CL CL2019000909A patent/CL2019000909A1/en unknown
- 2019-05-10 ZA ZA2019/02933A patent/ZA201902933B/en unknown
- 2019-11-28 CL CL2019003485A patent/CL2019003485A1/en unknown

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130266560A1 (en) *	2011-04-08	2013-10-10	University Of Leicester	Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
WO2012151481A1 (en) *	2011-05-04	2012-11-08	Omeros Corporation	Compositions for inhibiting masp-2 dependent complement acitivation
WO2015058143A1 (en) *	2013-10-17	2015-04-23	Omeros Corporation	Methods for treating conditions associated with masp-2 dependent complement activation
US20180153988A1 (en) *	2016-08-31	2018-06-07	Omeros Corporation	Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods

Also Published As

Publication number	Publication date
JP2019534271A (en)	2019-11-28
NZ753260A (en)	2021-11-26
IL265981A (en)	2019-06-30
PH12019500711A1 (en)	2019-11-18
AU2017342428A1 (en)	2019-05-23
KR20190063475A (en)	2019-06-07
JOP20190068A1 (en)	2019-04-01
MA46541A (en)	2019-08-21
GEP20247587B (en)	2024-01-25
KR102348939B1 (en)	2022-01-12
SG11201902941UA (en)	2019-05-30
IL265981B1 (en)	2025-01-01
MX2019004074A (en)	2019-06-10
JP6893554B2 (en)	2021-06-23
WO2018071701A1 (en)	2018-04-19
PH12019500711B1 (en)	2024-04-17
CA3039927A1 (en)	2018-04-19
BR112019007426A2 (en)	2019-07-02
CL2019000909A1 (en)	2019-06-14
CL2019003485A1 (en)	2020-04-13
IL265981B2 (en)	2025-05-01
AU2017342428B2 (en)	2021-02-04
EP3525798A1 (en)	2019-08-21
CA3039927C (en)	2023-10-10
CA3210384A1 (en)	2018-04-19
CN110177557A (en)	2019-08-27
ZA201902933B (en)	2023-05-31
UA126908C2 (en)	2023-02-22
MY205849A (en)	2024-11-15
CN116726163A (en)	2023-09-12

Publication	Publication Date	Title
IL271440B (en)	2020-08-31	Method and system for defect classification
IL285052B (en)	2022-03-01	Method and system for edge-of-wafer inspection and review
IL248241A0 (en)	2017-01-31	System and method for assessing cybersecurity awareness
EP4002951C0 (en)	2024-10-23	SYSTEM AND METHOD FOR BEAM-BASED PHYSICAL DIRECT ACCESS
GB201616723D0 (en)	2016-11-16	System and method for inspecting road surfaces
EP3463086A4 (en)	2020-01-22	SYSTEM AND METHOD FOR EVALUATING ADVANCED KINETIC SYMPTOMS
EP4254988C0 (en)	2024-12-11	APPARATUS AND METHOD FOR SCREEN-RELATED AUDIO OBJECT RE-MAPPING
PL3267348T3 (en)	2020-11-16	Method and apparatus for recognizing risk behavior
SI3160361T1 (en)	2019-09-30	Analysis cartridge and method for using same
EP3984761C0 (en)	2025-10-15	METHOD FOR SMOOTHER TOTAL RESPONSE IN FLEXO PRINTING
EP3287811C0 (en)	2024-06-12	METHOD, APPARATUS AND COMPUTER-READABLE STORAGE MEDIUM FOR GNSS POINT POSITIONING
GB2558480B (en)	2019-02-06	Method and system for determining pedestrian flows
DE112016000336A5 (en)	2017-10-19	A method for performing a lane change in a Krafffahrzeug
HUE048491T2 (en)	2020-07-28	Method for determining drought tolerance in maize
DK3270111T3 (en)	2019-05-20	METHOD AND SYSTEM FOR TESTING AND CALIBRATING WIRELESS CONSUMERS
EP3525798A4 (en)	2020-07-08	METHOD FOR REDUCING PROTEINURIA IN A HUMAN TEST Suffering From Immunoglobulin-A Nephropathy
EP3398102A4 (en)	2020-07-08	PROTEOMIC DOCKING METHOD FOR IDENTIFYING PROTEIN-LIGAND INTERACTIONS
IL254928A0 (en)	2017-12-31	Methods for selecting phosphatase selective and non-selective phosphatase inhibitors
GB201503866D0 (en)	2015-04-22	Method and system for determining a residual load
GB201405723D0 (en)	2014-05-14	A system and method for testing a workflow
EP3452936A4 (en)	2020-01-15	CHECKPOINT ERROR AND METHOD FOR THEM
DE112016005845T8 (en)	2018-10-31	Apparatus and method for on-chip reliability controller
DK3365658T3 (en)	2022-09-05	TESTING APPARATUS AND METHOD
PT3442657T (en)	2022-10-13	Method for evaluating articular joint therapeutics
PL3523029T3 (en)	2021-11-29	Method for testing a sample

Legal Events

Date	Code	Title	Description
2018-04-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-07-19	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-07-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-08-21	17P	Request for examination filed	Effective date: 20190503
2019-08-21	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-08-21	AX	Request for extension of the european patent	Extension state: BA ME
2020-05-29	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031710500 Ipc: A61K0039395000
2020-07-08	A4	Supplementary search report drawn up and despatched	Effective date: 20200605
2020-07-08	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/00 20060101ALI20200529BHEP Ipc: A61K 39/395 20060101AFI20200529BHEP Ipc: A61K 45/06 20060101ALI20200529BHEP Ipc: A61P 13/12 20060101ALI20200529BHEP Ipc: C07K 16/40 20060101ALI20200529BHEP
2023-05-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-06-07	17Q	First examination report despatched	Effective date: 20230508
2024-02-21	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20240112